# The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients

> **NCT02044692** · — · UNKNOWN · sponsor: **Green Cross Corporation** · enrollment: 34 (estimated)

## Conditions studied

- Hunter Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02044692
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2020-01
- **Final completion:** 2020-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2014-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044692, "The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02044692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*